Skip to main content

Table 3 Primary endpoint analysis and therapeutic efficacy

From: Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia

 

Treatment assignment

Relapse control

AS + PQ

AS-PYR + PQ

DHA-PP + PQ

Subjects

60

60

60

41

Withdrawals

2

1

0

0

Relapses

10

9

7

32

Efficacy by incidence density

Person-years at risk

50.17

53.62

55.00

11.83

Relapse incidence density (attacks/person-yr)

0.20

0.17

0.13

2.71

Efficacy (%) against relapse (95 % CI)

92.2 (83.4 – 96.6)

93.5 (85.7 – 97.3)

95.0 (88.3 – 98.2)

na

Efficacy by proportion relapse-free at 6 months

Relapses within 6 months

10

7

7

na

% free of recurrence at 6 Months

83

88

88

na

  1. AS artesunate, PQ primaquine, PYR pyronaridine, DHA-PP dihydroartemisinin-piperaquine